1-5 of 5
Matthew Squires
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

Paola Guglielmelli, PhD MD, Giada Rotunno, BiSci, Costanza Bogani, PhD, Carmela Mannarelli, MSc, Matthew Squires, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Alessandro M. Vannucchi, MD
Journal: Blood
Blood (2014) 124 (21): 1853.
https://doi.org/10.1182/blood.V124.21.1853.1853
Published: 2014
Journal Articles

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

Clinical Trials & Observations Brief Report
Paola Guglielmelli, Flavia Biamonte, Giada Rotunno, Valentina Artusi, Lucia Artuso, Isabella Bernardis, Elena Tenedini, Lisa Pieri, Chiara Paoli, Carmela Mannarelli, Rajmonda Fjerza, Elisa Rumi, Viktoriya Stalbovskaya, Matthew Squires, Mario Cazzola, Rossella Manfredini, Claire Harrison, Enrico Tagliafico, Alessandro M. Vannucchi
Journal: Blood
Blood (2014) 123 (14): 2157–2160.
https://doi.org/10.1182/blood-2013-11-536557
Published: 2014
Includes: Supplemental data
Journal Articles

The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT)

Matthew Squires, PhD, Claire N Harrison, DM, FRCP, FRCPath, Giovanni Barosi, MD, Alessandro M Vannucchi, MD, Tiziano Barbui, MD, Heinz Gisslinger, Francesco Passamonti, MD, Haifa Kathrin Al-Ali, MD, Jean-Jacques Kiladjian, MD, PhD, Mahtab T. Marker, PhD, Estella T. Mendelson, BSRN, MBA, Viktoriya Stalbovskaya, PhD, Francisco Cervantes, MD, PhD, Laurent Knoops, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4070.
https://doi.org/10.1182/blood.V122.21.4070.4070
Published: 2013
Journal Articles

Impact Of Prognostically Detrimental Mutations ( ASXL1, EZH2, SRSF2, IDH1/2 ) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II

Paola Guglielmelli, PhD MD, Flavia Biamonte, BiSci, PhD, Lisa Pieri, MD PhD, Giada Rotunno, BiSci, Chiara Paoli, BiSci, Rajmonda Fjerza, MD, Enrico Tagliafico, MD PhD, Rossella Manfredini, PhD, Valentina Artusi, MSc, Elena Tenedini, PhD, Lucia Artuso, PhD, Isabella Bernardis, Viktoriya Stalbovskaya, PhD, Matthew Squires, PhD, Claire N Harrison, DM, FRCP, FRCPath, Alessandro M Vannucchi, MD
Journal: Blood
Blood (2013) 122 (21): 107.
https://doi.org/10.1182/blood.V122.21.107.107
Published: 2013
Journal Articles

Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT)

Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Haifa Kathrin Al-Ali, MD, Giovanni Barosi, MD, Claire N Harrison, DM FRCP FRCPath, Andres Sirulnik, MD, PhD, Viktoriya Stalbovskaya, PhD, Matthew Squires, PhD, Timothy Burn, PhD, Laurent Knoops, MD, PhD, Francisco Cervantes, MD, Tiziano Barbui, MD, Heinz Gisslinger, MD, Jean-Jacques Kiladjian, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 802.
https://doi.org/10.1182/blood.V120.21.802.802
Published: 2012